Premier Biomedical announced yesterday that it will present positive results from duplicated testing on mice that demonstrate statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical’s anti-breast cancer treatment compared to both chemotherapy and a non-treated control group. The data will be presented at the American Association for Cancer Research’s annual meeting, which is being held this year in San Diego, California from April 5-9, 2014.
Premier Biomedical focuses on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer’s disease and traumatic brain injury. The company’s Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, also a co-author of the work, considers that these results represent “a major step” in the prevention of breast cancer metastasis and the defeat of cancer in a nontoxic manner, by utilizing the body’s own immune system. “The AACR conference is one of the most prestigious venues in the world for presenting cutting-edge cancer research,” he said.
The presentation for the Poster Session at the annual conference is being developed by Premier Biomedical and its two established partners in R&D, the University of Texas at El Paso and the Department of Defense, with Center of Expertise at the William Beaumont Army Medical Center. In addition, the University of Pisa, Italy, and the University of Toronto, Canada, collaborated in the development of the research.
“We are extremely pleased to see the exciting results of our proprietary breast cancer medication study finally made public via the AACR,” stated Premier Biomedical CEO William A. Hartman. “These study results provide important pre-clinical validation and peer review for our medication as a successful treatment for breast cancer and help to build a foundation to advance our candidate anti-breast cancer medication toward our internal goal of initiating human clinical trials this year.”